Investigators at Southern Methodist University and The University of Texas at Dallas have discovered a family of small molecules that shows promise in protecting brain cells against nerve-degenerative diseases such as Parkinson's, Alzheimer's and Huntington's, which afflict millions.
Dallas-based startup EncephRx, Inc. was granted the worldwide license to the jointly owned compounds. A biotechnology and therapeutics company, EncephRx will develop drug therapies based on the new class of compounds as a pharmaceutical for preventing nerve-cell damage, delaying onset of degenerative nerve disease and improving symptoms.
Treatments currently in use don't stop or reverse degenerative nerve diseases, but instead only alleviate symptoms, sometimes with severe side effects. If proved effective and nontoxic in humans, EncephRx's small-molecule pharmaceuticals would be the first therapeutic tools able to stop affected brain cells from dying.
"Our compounds protect against neurodegeneration in mice," said synthetic organic chemist Edward R. Biehl, the SMU Department of Chemistry professor who led development of the compounds at SMU. "Given successful development of the compounds into drug therapies, they would serve as an effective treatment for patients with degenerative brain diseases."
EncephRx initially will focus its development and testing efforts toward Huntington's disease and potentially will have medications ready for human trials in two years, said Aaron Heifetz, CEO at EncephRx.Compounds developed by SMU and UTD collaboration
"Additional research needs to be done, but these compounds have the potential for stopping or slowing the relentless loss of brain cells in diseases such as Alzheimer's and Parkinson's," said D'Mello, professor of molecular and cell biology at UT Dallas, with a joint appointment in the School of Brain and Behavioral Science. "The protective effect that they display in tissue culture and animal models of neurodegenerative disease provides strong evidence of their promise as drugs to treat neurodegenerative disorders."Millions are suffering, particularly the elderly
The diseases steadily erode motor skills, including speech and the ability to walk, cause tremors, slowed movement, stooped posture, memory loss and mood and behavior problems.
The risk of developing a degenerative nerve disease increases with age. These diseases affect more than 5 million Americans.Novel compounds effectively proved protective in initial studies
The most promising lead compound, designated HSB-13, was tested in Huntington's disease animal models. It not only reduced degeneration in a part of the forebrain but also improved behavioral performance while proving nontoxic. The compound also was efficacious in a commonly used fly model of Alzheimer's disease.
"These preliminary tests demonstrated that the compound was an extremely potent neuroprotective agent," Biehl said.
The findings were published in the article "Identification of novel 1,4-benzoxazine compounds that are protective in tissue culture and in vivo models of neurodegeneration," which appeared in the Journal of Neuroscience Research. The National Institutes of Health and the Defense Advanced Research Projects Agency funded the project.
The SMU and UT Dallas researchers developed and tested more than 100 compounds for neuroprotective efficacy and toxicity over the course of four years before making the discovery in 2007.Interinstitutional partnership with EncephRx
"While discovery of the compounds is a major accomplishment, many hurdles remain," Biehl said.
EncephRx is a university spinout formed to develop and commercialize the compounds. Its management team has proven success in all facets of drug development and has developed more than a dozen chemical compounds.
Aaron Heifetz, president and chief executive officer of EncephRx, Inc., said, "We believe this library of novel neuroprotective compounds will prove an important step in the effort to improve the health for patients with neurodegenerative diseases, such as Huntington's disease, Alzheimer's disease and Parkinson's disease."
Chris Jeffers, managing partner of FirstStage Bioventures, the parent company of EncephRx, added, "FirstStage is very excited about this technology and looks forward to helping EncephRx quickly move these compounds into the clinic."
SMU has an uplink facility on campus for live TV, radio or online interviews. To speak with Dr. Biehl or Dr. D'Mello or to book them in the SMU studio, call SMU News & Communications at 214-768-7650 or UT Dallas Office of Media Relations at 972-883-4321.
SMU is a private university in Dallas where nearly 11,000 students benefit from the national opportunities and international reach of SMU's seven degree-granting schools. For more information see www.smu.edu.
Margaret Allen | EurekAlert!
Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM
More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.
Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...
Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.
"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...
The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.
Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...
The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...
Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.
Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...
28.04.2017 | Event News
20.04.2017 | Event News
18.04.2017 | Event News
28.04.2017 | Medical Engineering
28.04.2017 | Earth Sciences
28.04.2017 | Life Sciences